Membership
The REMS Industry Consortium (RIC) brings together the Risk Evaluation and Mitigation Strategies industry to advance patient safety and innovation in the implementation of new drugs and biologics. By joining RIC, you can gain knowledge, experience, and professional affiliations that will put you at the forefront of REMS industry advancements. Through RIC networking opportunities, you will make vital connections with other professionals in this space who share your desire for collaboration and guidance in addressing industry challenges.
Membership dues for pharmaceutical manufacturers for 2026 are:
Founding Members: $55,000
Board Members (Board Seat and 5 or more participants from organization): $50,000
Enterprise Members (5 or more participants from organization): $15,750
Group Members (1-4 participants from organization): $5,250
Current RIC Members include:
Amneal Pharmaceuticals
Apellis Pharmaceuticals, Inc.
Apotex
Ascend Laboratories LLC, a subsidiary of Alkem Laboratories Ltd
AstraZeneca Pharmaceuticals LP
Avadel Pharmaceuticals
Bristol Myers Squibb
Compass Pathways
Endo USA, Inc.
Gilead Sciences
GSK
Hikma Pharmaceuticals USA Inc.
Johnson & Johnson Innovative Medicine
Jazz Pharmaceuticals
Novartis
Pfizer Inc.
Regeneron
Sandoz
Sanofi
Sun Pharma
Takeda
Tasman Pharma Inc.
Teva Pharmaceuticals
UCB, Inc.
Viatris
Current Industry Partners include:
APCER Life Sciences
Axian Consulting, Ltd.
ConnectiveRx
Hawthorne Health
Integrated Pharmacy Solutions
Invaryant, LLC
KPMG
Maryann Major, Inc.
MMS Holdings Inc
MVG Consulting Services, Inc.
Perspective Pharmacovigilance
PPD, part of Thermo Fisher Scientific
Shepherd Safety Services
Syneos Health
United BioSource, LLC
Venebio Group, LLC